Nine-month clinical outcomes in patients with diabetes treated with polymer-free sirolimus-eluting stents and 6‑month vs. 12‑month dual-antiplatelet therapy (DAPT)

Krackhardt, Florian; Waliszewski, Matthias; Rischner, Jérôme; Piot, Christophe; Pansiéri, Michel; Ruíz-Poveda, Fernando Lozano; Boxberger, Michael; Noutsias, Michel; Rios, Xacobe Flores; Kherad, Behrouz

doi:10.1007/s00059-017-4675-x

Cited by 7 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MI, and all-cause death [31]. Based on these findings, they suggested that short-term DAPT was a reasonable strategy for patients with DM after PCI.…”

Section: Plos Onementioning

confidence: 91%

Short- versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes mellitus: A meta-analysis of randomized controlled trials

Zhang

Huang

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Background Diabetes is considered to be a high-risk factor for thromboembolic events. However, available data about the optimal dual antiplatelet therapy (DAPT) in patients with diabetes mellitus (DM) after second-generation drug-eluting stent (DES) implantation are scant. Objective The purpose of this study was to compare the impact of various DAPT durations on clinical outcomes in patients with DM after second-generation DES implantation. Methods We searched PubMed, Embase, and the Cochrane Library for studies that compared short-term (≤ 6 months) and long-term (≥ 12 months) DAPT in patients with DM. The primary endpoints were late (31–365 days) and very late (> 365 days) stent thrombosis (ST). The secondary endpoints included myocardial infarction (MI), target vessel recanalization (TVR), all-cause death, and major bleeding. Results Six randomized controlled trials, with a total of 3,657 patients with DM, were included in the study. In terms of the primary endpoint, there was no significant difference between the two groups in late (OR 1.15, 95% CI: 0.42–3.19, P = 0.79) or very late (OR 2.18, 95% CI: 0.20–24.18; P = 0.53) ST. Moreover, there was no significant difference in the secondary endpoints, including MI (OR 1.11, 95% CI: 0.72–1.71, P = 0.63), TVR (OR 1.31, 95% CI: 0.82–2.07, P = 0.26), all-cause death (OR 1.03, 95% CI: 0.61–1.75, P = 0.90) and major bleeding (OR 1.07, 95% CI: 0.34–3.40, P = 0.90) between the two groups. Conclusion Our study demonstrated that compared with long-term DAPT, short-term DAPT had no significant difference in the clinical outcomes of patients with DM implanted with second-generation DES.

show abstract

“…MI, and all-cause death [31]. Based on these findings, they suggested that short-term DAPT was a reasonable strategy for patients with DM after PCI.…”

Section: Plos Onementioning

confidence: 91%

Short- versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes mellitus: A meta-analysis of randomized controlled trials

Zhang

Huang

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…To support the results of this analysis, the International ISAR 2000 All Corner Registry also showed no significant difference in the stent thrombosis rate with short- versus long-term DAPT use following PCI [15]. One out of 165 and 340 participants with short- (≤ 6 months) and long-term (> 6 months) DAPT use, respectively, suffered late stent thrombosis.…”

Section: Discussionmentioning

confidence: 65%

Duration of Dual Antiplatelet Therapy and Late Stent Thrombosis Following Percutaneous Coronary Intervention with Second-Generation Drug-Eluting Stents: A Simple Meta-Analysis of Randomized Controlled Trials

Zhong

et al. 2019

Adv Ther

View full text Add to dashboard Cite

IntroductionThe aim of this simple meta-analysis was to systematically compare the occurrence of late and very late stent thrombosis with a short versus a longer duration of dual anti-platelet therapy (DAPT) use following the implantation of second-generation drug-eluting stents (DES).MethodsRandomized controlled trials that compared short- and long-term DAPT use following percutaneous coronary intervention (PCI) with DES and that reported late (> 30 days but < 1 year) and very late (> 1 year) stent thromboses were searched from the bibliographic database of life sciences and biomedical information, which is also known as MEDLINE, as well as other searched databases including EMBASE, the Cochrane Central and http://www.ClinicalTrials.com. Statistical analysis was carried out using RevMan software [odds ratios (OR) and 95% confidence intervals (CIs) represented the results].ResultsThis simple analysis consisted of five randomized controlled trials with a total of 7142 patients. The current results showed no significant difference in late stent thrombosis associated with a shorter or longer duration of DAPT use (OR 0.98, 95% CI 0.30–3.18; P = 0.97, I2 = 0%). The result for very late stent thrombosis was also not significantly different (OR 0.30, 95% CI 0.03–2.95; P = 0.31).ConclusionsThis simple analysis showed no impact of DAPT duration on the occurrence of late and very late stent thrombosis. Similar late and very late stent thrombosis rates were observed with 6-month versus 12-month duration of DAPT use following PCI with second-generation DES.

show abstract

“…Of 3506 articles, 652 were excluded after removing duplicates, 2830 were excluded after reviewing the title and abstract, and additional six studies were excluded because they contained unpublished data, were observational trials, or could not be grouped appropriately [24,25,26,27,28,29] (Figure 1). Eighteen trials were ultimately included with a total of 20536 diabetes patients randomly assigned to receive either short-term (≤3 months), midterm (6 months), standard-term (12 months), or extended-term (>12 months) DAPT regimens [10,11,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45].…”

Section: Search Results and Study Characteristicmentioning

confidence: 99%

Optimum duration of dual antiplatelet therapy followed by monotherapy for diabetes after percutaneous coronary intervention with drug-eluting stent implantation: a Bayesian network meta-analysis

An¹,

Guo²,

Qiu³

et al. 2021

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only.

show abstract

Nine-month clinical outcomes in patients with diabetes treated with polymer-free sirolimus-eluting stents and 6‑month vs. 12‑month dual-antiplatelet therapy (DAPT)

Cited by 7 publications

References 33 publications

Short- versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes mellitus: A meta-analysis of randomized controlled trials

Short- versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes mellitus: A meta-analysis of randomized controlled trials

Duration of Dual Antiplatelet Therapy and Late Stent Thrombosis Following Percutaneous Coronary Intervention with Second-Generation Drug-Eluting Stents: A Simple Meta-Analysis of Randomized Controlled Trials

Optimum duration of dual antiplatelet therapy followed by monotherapy for diabetes after percutaneous coronary intervention with drug-eluting stent implantation: a Bayesian network meta-analysis

Contact Info

Product

Resources

About